News archive
Showing 650 results
September 2011
-
Media Release
Novartis Drug Afinitor® Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing
-- Everolimus combined with hormonal therapy more than doubled time without tumor growth and reduced risk of progression by 57% vs hormonal therapy alone(1)-- Study shows everolimus significantly… -
Media Release
Novartis Drug Afinitor® Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing
-
Media Release
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
- Phase III IMPRES study demonstrates potential benefits of QTI571 in patients who remain symptomatic despite treatment with two or more PAH therapies(1)- Evidence indicates that QTI571 targets an… -
Media Release
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
-
Media Release
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
- Study met primary endpoint of kidney tumor response rate with 42% of patients on everolimus experiencing a response versus 0% on placebo(1)- Kidney tumors are present in up to 80% of patients with… -
Media Release
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
-
Media Release
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
- ACZ885, which neutralizes key inflammatory driver interleukin-1 beta[1], provided significant symptom improvement vs. placebo in Phase III pivotal trial[2]- Systemic juvenile idiopathic arthritis… -
Media Release
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
August 2011
-
Media Release
FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity
- Gilenya-treated patients had fewer T1 gadolinium (Gd)- enhancing lesions versus those treated with interferon beta-1a IM at 12 months and placebo at 24 months - More than 11,000 people in U.S. have… -
Media Release
FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity